ATM Financing Provides Effective Access to Cash

Biotechnology companies have an insatiable appetite for cash to fuel their drug development programs. However during the past several years, apart from the industry's "blue chip" companies, the majority of biotechs have been forced into a strict diet as financing has become more difficult and costly to secure. With follow-on financings becoming challenging and costly to complete given the current state of the capital markets, publicly listed companies are turning to alternative forms of financing. One of these vehicles is at-the-market (ATM) financing.